TY - JOUR
T1 - Adenosine Type A2A Receptor in Peripheral Cell from Patients with Alzheimer's Disease, Vascular Dementia, and Idiopathic Normal Pressure Hydrocephalus
T2 - A New/Old Potential Target
AU - Arosio, Beatrice
AU - Casati, Martina
AU - Gussago, Cristina
AU - Ferri, Evelyn
AU - Abbate, Carlo
AU - Scortichini, Valeria
AU - Colombo, Elena
AU - Rossi, Paolo Dionigi
AU - Mari, Daniela
PY - 2016/9/6
Y1 - 2016/9/6
N2 - As the European population gets older, the incidence of neurological disorders increases with significant impact on social costs. Despite differences in disease etiology, several brain disorders in the elderly (e.g., Alzheimer's disease, vascular dementia, normal pressure hydrocephalus) share dementia as a common clinical feature. The current treatment for the majority of these diseases is merely symptomatic and does not modify the course of the illness. Symptoms of normal pressure hydrocephalus are the only ones that can be modified if they are recognized in time and treated appropriately. Therefore, an important clinical strategy may be disclosed by pathogenic pathways that can be modified and to find drugs that can slow down or even arrest disease progression. Possibly a way to answer this question could be by re-examining all the molecules which have so far succeeded in improving many aspects of cognitive deterioration in some neurodegenerative conditions, that were not considered because of controversial opinions. The main purpose of this summary is to further substantiate the hypothesis that the pathway of adenosine type A2A receptor could be used as a potential target to develop new/old therapeutic strategies.
AB - As the European population gets older, the incidence of neurological disorders increases with significant impact on social costs. Despite differences in disease etiology, several brain disorders in the elderly (e.g., Alzheimer's disease, vascular dementia, normal pressure hydrocephalus) share dementia as a common clinical feature. The current treatment for the majority of these diseases is merely symptomatic and does not modify the course of the illness. Symptoms of normal pressure hydrocephalus are the only ones that can be modified if they are recognized in time and treated appropriately. Therefore, an important clinical strategy may be disclosed by pathogenic pathways that can be modified and to find drugs that can slow down or even arrest disease progression. Possibly a way to answer this question could be by re-examining all the molecules which have so far succeeded in improving many aspects of cognitive deterioration in some neurodegenerative conditions, that were not considered because of controversial opinions. The main purpose of this summary is to further substantiate the hypothesis that the pathway of adenosine type A2A receptor could be used as a potential target to develop new/old therapeutic strategies.
KW - Adenosine
KW - adenosine receptors
KW - elderly
KW - neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=84986582216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84986582216&partnerID=8YFLogxK
U2 - 10.3233/JAD-160324
DO - 10.3233/JAD-160324
M3 - Review article
AN - SCOPUS:84986582216
VL - 54
SP - 417
EP - 425
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
SN - 1387-2877
IS - 2
ER -